{"nctId":"NCT01790659","briefTitle":"Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama","startDateStruct":{"date":"2013-05"},"conditions":["Cutaneous Leishmaniasis"],"count":399,"armGroups":[{"label":"WR 279,396","type":"EXPERIMENTAL","interventionNames":["Drug: WR 279,396"]},{"label":"Paromomycin","type":"EXPERIMENTAL","interventionNames":["Drug: Paromomycin"]}],"interventions":[{"name":"WR 279,396","otherNames":["Paromomycin/Gentamicin topical cream"]},{"name":"Paromomycin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female at least 2 years-of-age\n* Subject or legal guardian able to give written informed consent or assent, as appropriate\n* Diagnosis of CL in at least one lesion by at least one of the following methods: 1) positive culture for promastigotes or 2) microscopic identification of amastigotes in stained lesion tissue\n* At least one ulcerative lesion ≥ 1 cm and ≤ 5 cm that has a diagnosis of CL\n* Willing to forego other forms of treatments for CL including other investigational treatments during the study\n* In the opinion of the investigator, subject (or their legal guardian), subject is capable of understanding and complying with the protocol\n* If female and of child-bearing potential, must have a negative serum pregnancy test during screening and agree to use an acceptable method of birth control during the treatment phase and for 1 week after treatment is completed\n\nExclusion Criteria:\n\n* Lesion due to leishmania that involves the nasal or oral mucosa or any signs of mucosal disease that might be due to Leishmania\n* Only a single lesion on the ear with erosive cartilage\n* Signs and symptoms of disseminated disease in the opinion of the investigator\n* More than 10 lesions\n* Female who is breast-feeding\n* Significant organ abnormality, chronic disease such as diabetes, severe hearing loss, evidence of renal or hepatic dysfunction, or creatinine, aspartate aminotransferase (AST), or alanine aminotransferase (ALT) greater than 15% above the upper limit of normal (ULN) as defined by the clinical laboratory defined normal ranges\n* Received treatment for leishmaniasis including any medication with pentavalent antimony including sodium stibogluconate (Pentostam™), meglumine antimoniate (Glucantime™); amphotericin B (including liposomal amphotericin B and amphotericin B deoxycholate); or other medications containing paromomycin (administered parenterally or topically) or methylbenzethonium chloride (MBCL); gentamicin; fluconazole; ketoconazole; pentamidine; miltefosine, azithromycin or allopurinol that was completed within 56 days of starting study treatments\n* History of known or suspected hypersensitivity or idiosyncratic reactions to aminoglycosides","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent of Participants With Final Clinical Cure","description":"The primary efficacy endpoint is percent of subjects with final clinical cure. Final clinical cure is defined as follows:\n\n* Subject has initial clinical cure (100% re-epithelialization of index lesion by nominal Day 63); OR,\n* Subject has initial clinical improvement (\\> 50% re-epithelialization of index lesion by nominal Day 63) followed by 100% re-epithelialization of the index lesion on or before nominal Day 100; AND,\n* Subject has no relapse of index lesion.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.6","spread":null},{"groupId":"OG001","value":"77.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With All Lesions Cured","description":"• Percentage of subjects with all lesions cured, defined as: Final clinical cure as defined in primary objective (which is based solely on the index lesion); AND, Cure of all other lesions by nominal Day 100 (100% re-epithelialization of all ulcerated lesions and resolution of all other types of lesions)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.1","spread":null},{"groupId":"OG001","value":"76.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of All Lesions Cured at Day 168 (Ignores Per Subject Cure Rate)","description":"Percentage of all lesions meeting criteria for clinical cure during the study at 168 day mark for mITT subjects","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.2","spread":null},{"groupId":"OG001","value":"83.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Area of Ulceration (mm^2) of the Index Lesion at Each Measurement Time Point","description":"Area of ulceration (mm\\^2) of the index lesion at each measurement time point for mITT subjects","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"153","spread":"137"},{"groupId":"OG001","value":"165","spread":"167"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"831","spread":"627"},{"groupId":"OG001","value":"928","spread":"986"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"677","spread":"602"},{"groupId":"OG001","value":"762","spread":"933"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.3","spread":"138"},{"groupId":"OG001","value":"96.1","spread":"188"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-84.1","spread":"156"},{"groupId":"OG001","value":"-69.9","spread":"172"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":"87.2"},{"groupId":"OG001","value":"33.9","spread":"100"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-123","spread":"144"},{"groupId":"OG001","value":"-132","spread":"157"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.9","spread":"119"},{"groupId":"OG001","value":"27.6","spread":"107"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-123","spread":"167"},{"groupId":"OG001","value":"-136","spread":"171"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":"85.9"},{"groupId":"OG001","value":"7.41","spread":"56.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-144","spread":"163"},{"groupId":"OG001","value":"-152","spread":"165"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.3","spread":"111"},{"groupId":"OG001","value":"1.37","spread":"9.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-147","spread":"171"},{"groupId":"OG001","value":"-160","spread":"161"}]}]}]},{"type":"SECONDARY","title":"Area of Ulceration (mm^2) All Treated Lesions at Each Measurement Time Point","description":"Area of ulceration (mm\\^2) of all treated lesions from baseline (before the start of treatment), and on Study Days 20, 35 ± 2 days, 49 ± 4 days, 63 ± 7 days, 100 ± 14 days, and 168 ± 14 days for mITT subjects. Data presented is as presented in the Final Clinical Study Report; any inconsistencies can't be changed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"115","spread":"152"},{"groupId":"OG001","value":"115","spread":"149"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"656","spread":"683"},{"groupId":"OG001","value":"699","spread":"897"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"533","spread":"632"},{"groupId":"OG001","value":"577","spread":"829"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.0","spread":"132"},{"groupId":"OG001","value":"66.1","spread":"159"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-62.8","spread":"167"},{"groupId":"OG001","value":"-51.9","spread":"146"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4","spread":"76.8"},{"groupId":"OG001","value":"23.9","spread":"88.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-93.8","spread":"160"},{"groupId":"OG001","value":"-92.1","spread":"132"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.9","spread":"94.6"},{"groupId":"OG001","value":"15.8","spread":"82.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-96.2","spread":"170"},{"groupId":"OG001","value":"-98.7","spread":"142"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.49","spread":"58.8"},{"groupId":"OG001","value":"4.64","spread":"42.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-113","spread":"166"},{"groupId":"OG001","value":"-109","spread":"143"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.14","spread":"87.7"},{"groupId":"OG001","value":"0.83","spread":"7.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-118","spread":"182"},{"groupId":"OG001","value":"-114","spread":"147"}]}]}]},{"type":"SECONDARY","title":"Median Time to Initial Clinical Cure for Index Lesions","description":"Median time to initial clinical cure for index lesions (100% re-epithelialization of the index lesion)","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.000","spread":null},{"groupId":"OG001","value":"48.000","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":201},"commonTop":["Nasopharyngitis","Dermatitis contact","Pruritus","Application site injury","Headache"]}}}